var data={"title":"Cutaneous B cell pseudolymphomas","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cutaneous B cell pseudolymphomas</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">Rein Willemze, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 16, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H244702076\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term cutaneous pseudolymphoma refers to a heterogeneous group of benign skin disorders that simulate cutaneous lymphomas histologically and sometimes clinically. Cutaneous pseudolymphomas can be separated into two major subtypes, pseudolymphomas mimicking a cutaneous B cell lymphoma (B cell pseudolymphomas) and pseudolymphomas mimicking a cutaneous T cell lymphoma (T cell pseudolymphomas) (<a href=\"image.htm?imageKey=DERM%2F102613\" class=\"graphic graphic_table graphicRef102613 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p>Cutaneous B cell pseudolymphomas (previously called lymphadenosis benigna cutis, lymphocytoma cutis, pseudolymphoma of Spiegler-Fendt, or cutaneous lymphoid hyperplasia) represent a reactive B-cell proliferation response to a variety of antigenic stimuli, including arthropod bites, gold pierced earrings, tattoo dyes, and drugs. They usually present as erythematous nodules or plaques that simulate indolent primary cutaneous B cell lymphomas, in particular primary cutaneous marginal zone lymphoma (PCMZL) or primary cutaneous follicle center lymphoma (PCFCL).</p><p>This topic will discuss the pathogenesis, clinical presentation, and differential diagnosis of B cell pseudolymphomas. Primary cutaneous B cell lymphomas, cutaneous T cell pseudolymphomas, and lymphomatoid papulosis are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous marginal zone lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-cutaneous-follicle-center-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous follicle center lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-cutaneous-large-b-cell-lymphoma-leg-type\" class=\"medical medical_review\">&quot;Primary cutaneous large B cell lymphoma, leg type&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas\" class=\"medical medical_review\">&quot;Cutaneous T cell pseudolymphomas&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">&quot;Lymphomatoid papulosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H244702157\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The overall incidence and prevalence of cutaneous B cell pseudolymphomas are unknown. They may occur at any age, but are more frequently seen in young adults. B cell pseudolymphomas caused by <em>Borrelia burgdorferi</em> infection often occur in children [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H244702163\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cutaneous B cell pseudolymphomas are localized reactive B-cell proliferations induced by various antigenic stimuli, including arthropod bites, vaccinations, acupuncture, gold pierced earrings, tattoo dyes (particularly red pigments), and drugs [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/1,5-13\" class=\"abstract_t\">1,5-13</a>]. In most cases, however, the cause of cutaneous B cell pseudolymphomas is unknown (idiopathic B cell pseudolymphomas).</p><p>B cell pseudolymphomas have been frequently associated with <em>B. burgdorferi</em> infection (borrelial lymphocytoma cutis) in Europe, in areas endemic for the <em>Ixodes ricinus</em> tick [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/14-16\" class=\"abstract_t\">14-16</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-lyme-disease-in-adults#H13\" class=\"medical medical_review\">&quot;Clinical manifestations of Lyme disease in adults&quot;, section on 'Cutaneous findings'</a>.)</p><p class=\"headingAnchor\" id=\"H244702281\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients present with a solitary skin-colored or red solitary nodule or plaque, preferentially located on the face or chest (<a href=\"image.htm?imageKey=DERM%2F103720\" class=\"graphic graphic_picture graphicRef103720 \">picture 1</a>). Scaling and ulceration are generally absent. Less frequently, patients present with multiple lesions within a circumscribed area (<a href=\"image.htm?imageKey=DERM%2F103719\" class=\"graphic graphic_picture graphicRef103719 \">picture 2</a>) or with generalized skin lesions [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/17\" class=\"abstract_t\">17</a>].</p><p><em>B. burgdorferi</em>-associated pseudolymphoma typically presents as a soft, bluish-red nodule or plaque at sites of <em>Borrelia</em> infection, such as the earlobes (<a href=\"image.htm?imageKey=DERM%2F103721\" class=\"graphic graphic_picture graphicRef103721 \">picture 3</a>), nipples, and scrotum [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/5,16\" class=\"abstract_t\">5,16</a>]. It develops weeks to months after the infection and is relatively frequent in children [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/4,18\" class=\"abstract_t\">4,18</a>]. In a review of 144 adult patients, borrelial lymphocytoma was located on the breast in 106 patients (74 percent), on the ear lobe in 27 (19 percent), and at other sites in 11 (7 percent). Concomitant erythema migrans was found in 104 of 144 patients (72 percent) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-lyme-disease-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations of Lyme disease in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H244703584\"><span class=\"h2\">Clinical course</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical course of B cell pseudolymphomas is variable. Some lesions may resolve spontaneously in several months or years. Drug-induced B cell pseudolymphomas may resolve after cessation of the offending drug [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Resolution of borrelial lymphocytoma occurs after a median time of two to eight weeks after starting antibiotic treatment [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/4,16,18\" class=\"abstract_t\">4,16,18</a>].</p><p>Progression of B cell pseudolymphoma to a malignant lymphoma is unlikely; reported cases may represent misdiagnosed cases of early CBCL. A proportion of cases classified as cutaneous B cell pseudolymphoma in the past are now considered to be low-grade malignant CBCL, in particular primary cutaneous marginal zone lymphoma [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/19,20\" class=\"abstract_t\">19,20</a>].</p><p class=\"headingAnchor\" id=\"H244702327\"><span class=\"h1\">PATHOLOGY</span></p><p class=\"headingAnchor\" id=\"H60294686\"><span class=\"h2\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On histologic examination, most cases of cutaneous B cell pseudolymphoma show nodular to diffuse mixed-cellular infiltrates throughout the entire dermis, often with formation of lymphoid follicles (<a href=\"image.htm?imageKey=DERM%2F103722\" class=\"graphic graphic_picture graphicRef103722 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/21,22\" class=\"abstract_t\">21,22</a>]. Reactive germinal centers are generally surrounded by well-formed mantle zones, but in rare cases they may become confluent, simulating a primary cutaneous follicle center lymphoma (PCFCL) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/5\" class=\"abstract_t\">5</a>]. A mixed infiltrate of small lymphocytes, histiocytes, eosinophils, and plasma cells can be observed between the lymphoid follicles. The epidermis is not involved and is separated from the dermal infiltrate by a distinct grenz zone.</p><p class=\"headingAnchor\" id=\"H244703610\"><span class=\"h2\">Immunophenotyping</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunohistochemical analysis of B cell pseudolymphoma usually shows distinct B- and T-cell compartments. Stainings for CD35 or CD21 properly visualize networks of follicular dendritic cells within reactive germinal centers (<a href=\"image.htm?imageKey=DERM%2F103722\" class=\"graphic graphic_picture graphicRef103722 \">picture 4</a>). The germinal center cells (centrocytes and centroblasts) have a normal CD20<sup>+</sup>, CD10<sup>+</sup>, BCL6<sup>+</sup>, BCL2<sup>-</sup> phenotype, show a polytypic staining pattern for immunoglobulin light chains, and a high proliferation rate as assessed by MIB-1 staining [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/22\" class=\"abstract_t\">22</a>]. Reported cases of B cell pseudolymphoma with monotypic plasma cells are now considered primary cutaneous marginal zone lymphoma (PCMZL) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H244702401\"><span class=\"h2\">Clonality analysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunoglobulin (Ig) gene rearrangement analysis is usually performed to differentiate between benign and malignant lymphoproliferations. Clonal Ig gene rearrangements have been found in a small subset of B cell pseudolymphomas, as defined by immunohistochemical criteria, but are detected in 60 to 80 percent of PCMZL and PCFCL [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/24-26\" class=\"abstract_t\">24-26</a>]. The demonstration of B-cell clonality therefore supports the diagnosis of cutaneous B cell lymphoma, but is by itself insufficient to make a definite diagnosis. (See <a href=\"#H244702439\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H60293791\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of B cell pseudolymphoma requires a representative biopsy. Excisional biopsies are preferred to punch biopsies, but if a punch biopsy is taken, the diameter should be at least 4 mm. The biopsy specimen is evaluated for morphology, growth pattern, and immunophenotype.</p><p>In areas endemic for Lyme disease, patients with cutaneous B cell pseudolymphomas should undergo laboratory investigations for <em>B. burgdorferi</em> infection. Serology and polymerase chain reaction (PCR) for <em>Borrelia</em> DNA on tissue sections should be performed [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=diagnosis-of-lyme-disease\" class=\"medical medical_review\">&quot;Diagnosis of Lyme disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H244702439\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>B cell pseudolymphomas should be differentiated from indolent types of cutaneous B cell lymphomas, including primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle center lymphoma (PCFCL), and from secondary skin localizations of systemic nodular lymphomas. (See <a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous marginal zone lymphoma&quot;</a> and <a href=\"topic.htm?path=primary-cutaneous-follicle-center-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous follicle center lymphoma&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H244702467\"><span class=\"h2\">Primary cutaneous marginal zone lymphoma</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical features</strong> &ndash;&nbsp;Both primary cutaneous marginal zone lymphoma (PCMZL) and B cell pseudolymphoma can present as a solitary nodule or tumor (<a href=\"image.htm?imageKey=HEME%2F66125\" class=\"graphic graphic_picture graphicRef66125 \">picture 5</a>). Presentation with multiple scattered nodules on the trunk <span class=\"nowrap\">and/or</span> upper arms is rarely seen in B cell pseudolymphoma and strongly suggests a diagnosis of PCMZL (<a href=\"image.htm?imageKey=HEME%2F52551\" class=\"graphic graphic_picture graphicRef52551 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma#H8\" class=\"medical medical_review\">&quot;Primary cutaneous marginal zone lymphoma&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Histology and immunophenotyping </strong>&ndash; Both PCMZL and B cell pseudolymphoma show nodular to diffuse infiltrates that may contain reactive germinal centers. PCMZL characteristically shows collections of plasma cells at the periphery of these infiltrates or in the subepidermal area (<a href=\"image.htm?imageKey=HEME%2F90907\" class=\"graphic graphic_picture graphicRef90907 \">picture 7</a>). Demonstration of monotypic plasma cells expressing either kappa or lambda light chains by immunohistochemistry or in situ hybridization on paraffin sections is generally used as a decisive criterion for PCMZL [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/19,28\" class=\"abstract_t\">19,28</a>]. However, monotypic plasma cells may be scant and undetectable in recurrent lesions. (See <a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma#H9\" class=\"medical medical_review\">&quot;Primary cutaneous marginal zone lymphoma&quot;, section on 'Pathologic features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clonality analysis</strong> &ndash; (See <a href=\"#H244702401\" class=\"local\">'Clonality analysis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H330701885\"><span class=\"h3\">Are cutaneous B cell pseudolymphoma and PCMZL a disease spectrum?</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon the overlapping clinical and histologic features and the observation that both PCMZL and B cell pseudolymphomas may develop from chronic stimulation by intradermally applied antigens, it has been suggested that they may represent a continuous spectrum of cutaneous B-cell proliferations progressing from a reactive to a neoplastic state [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/1\" class=\"abstract_t\">1</a>]. There is an ongoing discussion on whether PCMZL, or at least a major subset of PCMZL with extremely indolent behavior, should or not be considered an overt malignant lymphoma [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma\" class=\"medical medical_review\">&quot;Primary cutaneous marginal zone lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H244703106\"><span class=\"h2\">Primary cutaneous follicle center lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologically, primary cutaneous follicle center lymphoma (PCFCL) can show a follicular, follicular and diffuse, or diffuse growth pattern [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/23\" class=\"abstract_t\">23</a>]. Distinguishing B cell pseudolymphomas from PCFCL with a diffuse and partly follicular growth pattern (most cases) is generally not difficult, but differentiation from cases with a follicular growth pattern (minority of cases) can be a challenge.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical features</strong> &ndash;&nbsp;Most patients with a PCFCL present with multiple, sometimes confluent plaques and nodules in a circumscribed area of the trunk (<a href=\"image.htm?imageKey=HEME%2F73842\" class=\"graphic graphic_picture graphicRef73842 \">picture 8</a>) or head, particularly the scalp (<a href=\"image.htm?imageKey=HEME%2F50985\" class=\"graphic graphic_picture graphicRef50985 \">picture 9</a>) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/27,30\" class=\"abstract_t\">27,30</a>]. This clinical presentation is an important clue to the correct diagnosis. (See <a href=\"topic.htm?path=primary-cutaneous-follicle-center-lymphoma#H4\" class=\"medical medical_review\">&quot;Primary cutaneous follicle center lymphoma&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Histologic criteria</strong> &ndash; Histologic criteria used in the past, including the presence of a mixed cellular infiltrate preferentially located in the upper dermis (&quot;top-heavy&quot; as opposed to &quot;bottom-heavy&quot; in malignant lymphomas) and the presence of lymphoid follicles with formation of germinal centers, cannot reliably differentiate between B cell pseudolymphoma and CBCL [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/21\" class=\"abstract_t\">21</a>]. In contrast to the reactive follicles seen in B cell pseudolymphomas and PCMZL, the neoplastic follicles in PCFCL with a (partly) follicular growth pattern are ill defined and show a reduced or absent mantle zone, loss of polarization, no or few tangible body macrophages, and a monotonous population of medium-sized to large centrocytes with variable numbers of admixed centroblasts [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/22\" class=\"abstract_t\">22</a>] (see <a href=\"topic.htm?path=primary-cutaneous-follicle-center-lymphoma#H6\" class=\"medical medical_review\">&quot;Primary cutaneous follicle center lymphoma&quot;, section on 'Morphology'</a>). However, the distinction between reactive and neoplastic follicles can sometimes be difficult. The presence of many admixed eosinophils is rarely observed in CBCL and favors a diagnosis of B cell pseudolymphoma [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/5,21\" class=\"abstract_t\">5,21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Immunophenotype</strong> &ndash; The germinal center cells in both reactive germinal centers in B cell pseudolymphoma and PCMZL and neoplastic germinal centers in PCFCL with a follicular growth pattern have the same CD20<sup>+</sup>, CD10<sup>+</sup>, BCL6<sup>+</sup>, BCL2<sup>-</sup> phenotype. Strong expression of BCL6, CD10, and BCL2 should raise suspicion of systemic follicular lymphoma with secondary cutaneous involvement [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/31,32\" class=\"abstract_t\">31,32</a>]. However, this pattern may also be observed in a minority of PCFCL, but rarely in B cell pseudolymphomas. The presence of clusters of CD10 <span class=\"nowrap\">and/or</span> BCL6-positive cells outside the neoplastic follicles strongly suggests a diagnosis of PCFCL.</p><p/><p class=\"bulletIndent1\">In frozen sections, PCFCL may express monotypic surface immunoglobulin (sIg) or the cells may lack sIg, whereas B cell pseudolymphomas show a polytypic sIg light chain expression [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/24\" class=\"abstract_t\">24</a>]. Examination of paraffin sections for sIg is generally not useful because of the low sIg expression by germinal center cells and the high background staining.</p><p/><p class=\"bulletIndent1\"><strong>Clonality analysis</strong> &ndash; (See <a href=\"#H244702401\" class=\"local\">'Clonality analysis'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H244703357\"><span class=\"h2\">Secondary cutaneous follicular lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic follicular lymphoma, the second most common type of non-Hodgkin lymphoma, can secondarily involve the skin. Secondary skin involvement may present as generalized nodules and tumors or as a solitary tumor, most commonly located on the head.</p><p>Histologically, these lesions show a diffuse infiltrate containing many neoplastic lymphoid follicles. The neoplastic germinal center cells show strong expression of BCL6, CD10, and BCL2 [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/32,33\" class=\"abstract_t\">32,33</a>]. In most cases, the translocation t(14;18) can be demonstrated by fluorescence in situ hybridization (FISH). (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-diagnosis-and-prognosis-of-follicular-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H244703419\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>B cell pseudolymphoma is an uncommon disorder. Evidence regarding treatment is mainly derived from small series of cases or single-case reports. The approach to treatment depends upon the number of lesions, their location, the presence of symptoms (eg, pruritus), the identification of an inciting cause, and patient preference.</p><p>Because B cell pseudolymphomas may resolve spontaneously over time, observation may be an option for patients with asymptomatic lesions who have negative tests for <em>B. burgdorferi</em>. In clinical practice, however, lesions are often initially treated with topical superpotent corticosteroids or intralesional corticosteroids. There are isolated reports of refractory lesions successfully treated with radiotherapy [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/34,35\" class=\"abstract_t\">34,35</a>], <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/36,37\" class=\"abstract_t\">36,37</a>], and intralesional <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/38\" class=\"abstract_t\">38</a>]. Solitary lesions may be excised surgically. Drug-induced B cell pseudolymphomas may resolve after cessation of the offending drug [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Patients with <em>B. burgdorferi</em>-associated B cell pseudolymphoma (borrelial lymphocytoma) should be treated for Lyme disease. We suggest treating borrelial lymphocytoma as early Lyme disease (<a href=\"image.htm?imageKey=ID%2F59949\" class=\"graphic graphic_table graphicRef59949 \">table 2</a>). (See <a href=\"topic.htm?path=treatment-of-lyme-disease#H4\" class=\"medical medical_review\">&quot;Treatment of Lyme disease&quot;, section on 'Early disease'</a>.)</p><p>In a review of 33 children with borrelial lymphocytoma, antibiotic treatment resulted in the resolution of the skin lesions in a median time of 16 days [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/18\" class=\"abstract_t\">18</a>]. In another study including 56 children with borrelial lymphocytoma, treatment with <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a> or phenoxymethyl penicillin cleared the skin lesions in a median time of two months after initiating antibiotic treatment [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/4\" class=\"abstract_t\">4</a>]. In a study of 144 adult patients with borrelial lymphocytoma, the skin lesions disappeared within a median time of 21 days after the start of treatment; treatment failures occurred in 14 of 144 patients (9.7 percent) [<a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H330702634\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous B cell pseudolymphomas (previously called lymphadenosis benigna cutis, lymphocytoma cutis, pseudolymphoma of Spiegler-Fendt, or cutaneous lymphoid hyperplasia) represent a reactive B-cell proliferation response to a variety of antigenic stimuli, including arthropod bites, <em>Borrelia</em> infection, gold pierced earrings, tattoo dyes, and drugs. (See <a href=\"#H244702076\" class=\"local\">'Introduction'</a> above and <a href=\"#H244702163\" class=\"local\">'Etiology and pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients present with a solitary skin-colored or red solitary nodule or plaque, preferentially located on the face or chest (<a href=\"image.htm?imageKey=DERM%2F103720\" class=\"graphic graphic_picture graphicRef103720 \">picture 1</a>). <em>Borrelia burgdorferi</em>-associated pseudolymphoma typically presents as a soft, bluish-red nodule or plaque at sites of <em>Borrelia</em> infection, such as the earlobes (<a href=\"image.htm?imageKey=DERM%2F103721\" class=\"graphic graphic_picture graphicRef103721 \">picture 3</a>), nipples, and scrotum. (See <a href=\"#H244702281\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of B cell pseudolymphoma requires a skin biopsy for histopathologic evaluation and immunophenotyping. In areas endemic for Lyme disease, patients with cutaneous B cell pseudolymphomas should undergo laboratory investigations for <em>B. burgdorferi</em> infection. (See <a href=\"#H60293791\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H244702327\" class=\"local\">'Pathology'</a> above and <a href=\"topic.htm?path=diagnosis-of-lyme-disease\" class=\"medical medical_review\">&quot;Diagnosis of Lyme disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>B cell pseudolymphomas may resolve spontaneously over time. In clinical practice, lesions are often initially treated with topical or intralesional corticosteroids. Refractory lesions may be treated with surgical excision or radiotherapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with <em>B. burgdorferi</em>-associated B cell pseudolymphoma (borrelial lymphocytoma) should be treated for Lyme disease. We suggest treating borrelial lymphocytoma as early Lyme disease (<a href=\"image.htm?imageKey=ID%2F59949\" class=\"graphic graphic_table graphicRef59949 \">table 2</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H244703419\" class=\"local\">'Treatment'</a> above and <a href=\"topic.htm?path=treatment-of-lyme-disease\" class=\"medical medical_review\">&quot;Treatment of Lyme disease&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/1\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Willemze R. Cutaneous pseudolymphomas: classification and differential diagnosis. Semin Dermatol 1994; 13:187.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/2\" class=\"nounderline abstract_t\">Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998; 38:877.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/3\" class=\"nounderline abstract_t\">Mitteldorf C, Kempf W. Cutaneous Pseudolymphoma. Surg Pathol Clin 2017; 10:455.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/4\" class=\"nounderline abstract_t\">Glatz M, Resinger A, Semmelweis K, et al. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. Acta Derm Venereol 2015; 95:565.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/5\" class=\"nounderline abstract_t\">Colli C, Leinweber B, M&uuml;llegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004; 31:232.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/6\" class=\"nounderline abstract_t\">Bernstein H, Shupack J, Ackerman B. Cutaneous pseudolymphoma resulting from antigen injections. Arch Dermatol 1974; 110:756.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/7\" class=\"nounderline abstract_t\">Iwatsuki K, Yamada M, Takigawa M, et al. Benign lymphoplasia of the earlobes induced by gold earrings: immunohistologic study on the cellular infiltrates. J Am Acad Dermatol 1987; 16:83.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/8\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Bruynzeel DP, Vos W, et al. Immunohistochemical studies of lymphadenosis benigna cutis occurring in a tattoo. Am J Dermatopathol 1988; 10:518.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/9\" class=\"nounderline abstract_t\">Cerroni L, Borroni RG, Massone C, et al. Cutaneous B-cell pseudolymphoma at the site of vaccination. Am J Dermatopathol 2007; 29:538.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/10\" class=\"nounderline abstract_t\">Paley K, Geskin LJ, Zirwas MJ. Cutaneous B-cell pseudolymphoma due to paraphenylenediamine. Am J Dermatopathol 2006; 28:438.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/11\" class=\"nounderline abstract_t\">Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol 2005; 52:623.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/12\" class=\"nounderline abstract_t\">Takahashi T, Hata M, Iwata H, Seishima M. Cutaneous B-cell Pseudolymphoma in a Psoriatic Patient Treated with Cyclosporine. Acta Derm Venereol 2016; 96:824.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/13\" class=\"nounderline abstract_t\">Riyaz N, Sasidharanpillai S, Aravindan KP, et al. Phenytoin Induced Cutaneous B Cell Pseudolymphoma. Indian J Dermatol 2015; 60:522.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/14\" class=\"nounderline abstract_t\">Li C, Inagaki H, Kuo TT, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol 2003; 27:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/15\" class=\"nounderline abstract_t\">Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001; 28:502.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/16\" class=\"nounderline abstract_t\">Maraspin V, Nahtigal Klevi&scaron;ar M, Ru&#382;i&#263;-Sablji&#263; E, et al. Borrelial Lymphocytoma in Adult Patients. Clin Infect Dis 2016; 63:914.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/17\" class=\"nounderline abstract_t\">Moreno A, Curc&oacute; N, Serrano T, et al. Disseminated, miliarial type lymphocytoma cutis. A report of two cases. Acta Derm Venereol 1991; 71:334.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/18\" class=\"nounderline abstract_t\">Arne&#382; M, Ru&#382;i&#263;-Sablji&#263; E. Borrelial Lymphocytoma in Children. Pediatr Infect Dis J 2015; 34:1319.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/19\" class=\"nounderline abstract_t\">Cerroni L, Signoretti S, H&ouml;fler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21:1307.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/20\" class=\"nounderline abstract_t\">Arai E, Shimizu M, Hirose T. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis. Hum Pathol 2005; 36:505.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/21\" class=\"nounderline abstract_t\">Rijlaarsdam JU, Meijer CJ, Willemze R. Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas. A comparative clinicopathologic study of 57 patients. Cancer 1990; 65:2301.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/22\" class=\"nounderline abstract_t\">Leinweber B, Colli C, Chott A, et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol 2004; 26:4.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/23\" class=\"nounderline abstract_t\">Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/24\" class=\"nounderline abstract_t\">Rijlaarsdam U, Bakels V, van Oostveen JW, et al. Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects. J Invest Dermatol 1992; 99:749.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/25\" class=\"nounderline abstract_t\">Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19:133.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/26\" class=\"nounderline abstract_t\">Nihal M, Mikkola D, Horvath N, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol 2003; 34:617.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/27\" class=\"nounderline abstract_t\">Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/28\" class=\"nounderline abstract_t\">Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993; 23:117.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/29\" class=\"nounderline abstract_t\">Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013; 139:515.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/30\" class=\"nounderline abstract_t\">Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106:2491.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/31\" class=\"nounderline abstract_t\">de Leval L, Harris NL, Longtine J, et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25:732.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/32\" class=\"nounderline abstract_t\">Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/33\" class=\"nounderline abstract_t\">de Leval L, Braaten KM, Ancukiewicz M, et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003; 27:1269.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/34\" class=\"nounderline abstract_t\">Taylor RB, Fortney JA, Pollack RB, et al. Radiation therapy for B-cell cutaneous lymphoid hyperplasia. Jpn J Radiol 2010; 28:385.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/35\" class=\"nounderline abstract_t\">Olson LE, Wilson JF, Cox JD. Cutaneous lymphoid hyperplasia: results of radiation therapy. Radiology 1985; 155:507.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/36\" class=\"nounderline abstract_t\">Benchikhi H, Bodemer C, Fraitag S, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999; 40:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/37\" class=\"nounderline abstract_t\">Pham-Ledard A, Vergier B, Doutre MS, Beylot-Barry M. Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. Dermatology 2010; 220:176.</a></li><li><a href=\"https://www.uptodate.com/contents/cutaneous-b-cell-pseudolymphomas/abstract/38\" class=\"nounderline abstract_t\">Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 2011; 11:286.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 102748 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H330702634\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H244702076\" id=\"outline-link-H244702076\">INTRODUCTION</a></li><li><a href=\"#H244702157\" id=\"outline-link-H244702157\">EPIDEMIOLOGY</a></li><li><a href=\"#H244702163\" id=\"outline-link-H244702163\">ETIOLOGY AND PATHOGENESIS</a></li><li><a href=\"#H244702281\" id=\"outline-link-H244702281\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H244703584\" id=\"outline-link-H244703584\">Clinical course</a></li></ul></li><li><a href=\"#H244702327\" id=\"outline-link-H244702327\">PATHOLOGY</a><ul><li><a href=\"#H60294686\" id=\"outline-link-H60294686\">Morphology</a></li><li><a href=\"#H244703610\" id=\"outline-link-H244703610\">Immunophenotyping</a></li><li><a href=\"#H244702401\" id=\"outline-link-H244702401\">Clonality analysis</a></li></ul></li><li><a href=\"#H60293791\" id=\"outline-link-H60293791\">DIAGNOSIS</a></li><li><a href=\"#H244702439\" id=\"outline-link-H244702439\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H244702467\" id=\"outline-link-H244702467\">Primary cutaneous marginal zone lymphoma</a><ul><li><a href=\"#H330701885\" id=\"outline-link-H330701885\">- Are cutaneous B cell pseudolymphoma and PCMZL a disease spectrum?</a></li></ul></li><li><a href=\"#H244703106\" id=\"outline-link-H244703106\">Primary cutaneous follicle center lymphoma</a></li><li><a href=\"#H244703357\" id=\"outline-link-H244703357\">Secondary cutaneous follicular lymphoma</a></li></ul></li><li><a href=\"#H244703419\" id=\"outline-link-H244703419\">TREATMENT</a></li><li><a href=\"#H330702634\" id=\"outline-link-H330702634\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/102748|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/103720\" class=\"graphic graphic_picture\">- B cell pseudolymphoma forehead</a></li><li><a href=\"image.htm?imageKey=DERM/103719\" class=\"graphic graphic_picture\">- B cell pseudolymphoma tattoo</a></li><li><a href=\"image.htm?imageKey=DERM/103721\" class=\"graphic graphic_picture\">- B cell pseudolymphoma Borrelia (borrelial lymphocytoma)</a></li><li><a href=\"image.htm?imageKey=DERM/103722\" class=\"graphic graphic_picture\">- B cell pseudolymphoma histo</a></li><li><a href=\"image.htm?imageKey=HEME/66125\" class=\"graphic graphic_picture\">- PCMZL solitary tumor on lower leg</a></li><li><a href=\"image.htm?imageKey=HEME/52551\" class=\"graphic graphic_picture\">- PCMZL multifocal skin lesions</a></li><li><a href=\"image.htm?imageKey=HEME/90907\" class=\"graphic graphic_picture\">- Classic PCMZL</a></li><li><a href=\"image.htm?imageKey=HEME/73842\" class=\"graphic graphic_picture\">- PCFCL chest</a></li><li><a href=\"image.htm?imageKey=HEME/50985\" class=\"graphic graphic_picture\">- PCFCL scalp</a></li></ul></li><li><div id=\"DERM/102748|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/102613\" class=\"graphic graphic_table\">- Cutaneous T and B pseudolymphomas</a></li><li><a href=\"image.htm?imageKey=ID/59949\" class=\"graphic graphic_table\">- Treatment of Lyme disease</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-lyme-disease-in-adults\" class=\"medical medical_review\">Clinical manifestations of Lyme disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-diagnosis-and-prognosis-of-follicular-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-t-cell-pseudolymphomas\" class=\"medical medical_review\">Cutaneous T cell pseudolymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-lyme-disease\" class=\"medical medical_review\">Diagnosis of Lyme disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphomatoid-papulosis\" class=\"medical medical_review\">Lymphomatoid papulosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-cutaneous-follicle-center-lymphoma\" class=\"medical medical_review\">Primary cutaneous follicle center lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-cutaneous-large-b-cell-lymphoma-leg-type\" class=\"medical medical_review\">Primary cutaneous large B cell lymphoma, leg type</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-cutaneous-marginal-zone-lymphoma\" class=\"medical medical_review\">Primary cutaneous marginal zone lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-lyme-disease\" class=\"medical medical_review\">Treatment of Lyme disease</a></li></ul></div></div>","javascript":null}